Press Releases

SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

Phase 1/2/3a and 3b study of ARCT-154 COVID-19 vaccine candidate completed enrollment   with over 17,000 participants Initiated ~2,000 participant ARCT-154 Phase 3c sub-study to compare immunogenicity noninferiority to AstraZeneca COVID-19 vaccine; enrollment to be completed this week Preparing to

SAN DIEGO --(BUSINESS WIRE)--Oct. 25, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

SAN DIEGO --(BUSINESS WIRE)--Oct. 21, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

SAN DIEGO --(BUSINESS WIRE)--Oct. 20, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

- Phase 3b dosing of ARCT-154 initiated; study designed to enroll approximately 20,000 participants - Initiation of Phase 3b study follows review of safety data from initial 1,000 Phase 1/2/3a participants - ARCT-154 remains on track for Emergency Use Authorization (EUA) filing in December 2021 SAN

SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

Phase 1 (100 participants): both doses completed Phase 2 (300 participants) has initiated Phase 3a (600 participants) on track to initiate by end of September Phase 3b (20,000 participants) dosing planned for first week of October ARCT-154 remains on track for Emergency Use Authorization (EUA)

SAN DIEGO --(BUSINESS WIRE)--Sep. 8, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory